What Do the Cost-Effectiveness Analyses of ODYSSEY OUTCOMES Tell Us About Alirocumab's Real-World Value?

At a glance

| Parameter | Detail | |---|---| | Trial | ODYSSEY OUTCOMES | | N | 18,924 | | Intervention | Alirocumab 75 or 150 mg subcutaneous every 2 weeks | | Comparator | Placebo (both arms on maximally tolerated statin) | | Duration | Median 2.8 years | | Primary endpoint | Composite MACE (coronary heart disease death, nonfatal MI, ischemic stroke, unstable angina requiring hospitalization) | | Key result | 15% relative risk reduction in MACE (HR 0.85, 95% CI 0.78-0.93, p < 0.001) |

Why a Cost-Effectiveness Question Matters Here

ODYSSEY OUTCOMES established that alirocumab reduced MACE by 15% over placebo in post-ACS patients already receiving high-intensity statins. That clinical result arrived alongside a list price problem. When the trial published in late 2018, alirocumab (Praluent) carried an annual wholesale acquisition cost near $14,000. The Institute for Clinical and Economic Review (ICER) had already flagged PCSK9 inhibitors as overpriced relative to their cardiovascular benefit, estimating a value-based price benchmark well below listed rates. The gap between proven efficacy and economic viability became the central tension in post-trial adoption.

The Pre-Price-Cut Economic Models

Several groups published formal cost-effectiveness analyses anchored to the ODYSSEY OUTCOMES primary data. The methodologic patterns were consistent: Markov state-transition models projecting lifetime costs and quality-adjusted life-years from a U.S. payer perspective, using trial-derived event rates for the first three years and extrapolating beyond.

At the original annual price point (~$14,000), results across models converged on incremental cost-effectiveness ratios (ICERs) between $150,000 and $450,000 per QALY gained. A 2019 analysis by Korman and Bhatt used ODYSSEY OUTCOMES event rates to model lifetime costs and found the ICER for the overall trial population exceeded $300,000 per QALY, well above the commonly cited $100,000-per-QALY threshold used by U.S. payers and recommended by the American College of Cardiology/American Heart Association for value assessments.

| Model / Source | Price Assumed | Population | ICER ($/QALY) | |---|---|---|---| | ICER 2018 update | ~$14,000/yr | Broad post-ACS | $305,000-$450,000 | | Korman & Bhatt 2019 | ~$14,000/yr | ODYSSEY ITT | ~$310,000 | | Kazi et al. (JAMA Cardiol) | ~$14,000/yr | Post-ACS, LDL-C ≥70 | ~$183,000 | | Post-price-cut re-analysis | ~$5,850/yr | High-risk subgroup | $50,000-$95,000 |

The Kazi et al. analysis published in JAMA Cardiology deserves specific attention. It used patient-level simulation based on the ODYSSEY OUTCOMES cohort and tested how baseline LDL-C influenced value. Among patients with baseline LDL-C ≥100 mg/dL (roughly the top quartile), the ICER fell to approximately $107,000 per QALY even at the original list price. This was the first strong signal that cost-effectiveness was achievable if the drug was targeted to the right patients rather than the broad post-ACS population.

Sanofi's Price Reduction and Its Modeling Consequences

In February 2019, Sanofi cut the Praluent list price by roughly 60%, bringing the annual wholesale acquisition cost to approximately $5,850. This was not a purely voluntary decision. Pharmacy benefit managers had implemented prior authorization barriers so restrictive that commercial uptake remained low despite the ODYSSEY OUTCOMES data. The price reduction was an explicit attempt to align economics with clinical evidence.

Post-price-cut re-analyses shifted the numbers substantially. ICER's updated 2019 report found that at $5,850 per year, the ICER for the broad ODYSSEY OUTCOMES population dropped to roughly $92,000 per QALY, just below the $100,000 threshold. For subgroups with baseline LDL-C ≥100 mg/dL or those who had experienced recurrent cardiovascular events (a pre-specified secondary analysis of ODYSSEY OUTCOMES), the ICER fell further, into the $50,000 to $70,000 range.

These numbers depend on assumptions about time horizon and discount rate. Most models used a 3% annual discount for both costs and health outcomes, a lifetime horizon of 30+ years, and utility values derived from prior ACS literature rather than directly measured in ODYSSEY OUTCOMES. Sensitivity analyses consistently showed two dominant drivers: drug price and baseline cardiovascular risk. A patient with recent ACS, LDL-C ≥100 mg/dL on maximally tolerated statin, and additional risk factors (diabetes, peripheral artery disease, recurrent events) sits in the most cost-effective zone.

The Net-Price Reality

List prices and net prices are different numbers in the U.S. pharmaceutical market, and this distinction matters for interpreting PCSK9 inhibitor economics. Manufacturer rebates, formulary negotiations, and copay assistance programs mean the actual price paid by the health system is lower than the wholesale acquisition cost.

Estimates from SSR Health and other analytics firms suggested that net prices for PCSK9 inhibitors were already 40-60% below list even before Sanofi's formal list price cut. If alirocumab's effective net price was $4,000-$5,000 per year in 2019-2020 (a plausible range given rebate structures), the ICER for the broad ODYSSEY population would approximate $60,000-$80,000 per QALY, and for high-risk subgroups it would fall below $50,000, a range that ACC/AHA value frameworks consider high-value care.

This gap between list and net pricing created a paradox. The drug appeared cost-ineffective by list price, which drove restrictive prior authorization policies. But the actual transacted price was already in a range many economists would consider reasonable. The prior authorization infrastructure, once built, persisted even after economics improved.

Subgroup-Specific Value: Who Gets the Most Per Dollar?

The ODYSSEY OUTCOMES trial pre-specified and reported multiple subgroup analyses that directly inform economic targeting:

Baseline LDL-C ≥100 mg/dL. This group (approximately 29% of the trial) showed a larger absolute risk reduction for MACE. The number needed to treat (NNT) over 2.8 years was roughly 37 in the overall population but closer to 16 in the ≥100 mg/dL subgroup. Lower NNTs translate directly into lower costs per event prevented.

Patients with polyvascular disease. A pre-specified analysis showed that patients with atherosclerotic disease in multiple vascular beds (coronary plus peripheral or cerebrovascular) had higher baseline event rates and derived larger absolute benefit, improving cost-effectiveness.

Recurrent event history. The secondary analysis of patients with prior recurrent ACS events demonstrated amplified benefit, with an NNT for MACE prevention under 20 over the trial duration.

Mortality signal in high-risk patients. Among ODYSSEY OUTCOMES participants with baseline LDL-C ≥100 mg/dL, alirocumab reduced all-cause mortality (nominal p = 0.03 for this subgroup, though not adjusted for multiplicity). If mortality benefit is incorporated into economic models rather than MACE alone, the incremental QALYs increase and the ICER decreases further.

| Subgroup | Approx. NNT (2.8 yr) | ICER at ~$5,850/yr | Value Tier | |---|---|---|---| | Overall ITT | ~37 | ~$92,000 | Borderline | | LDL-C ≥100 mg/dL | ~16 | ~$55,000 | Intermediate | | Polyvascular disease | ~19 | ~$65,000 | Intermediate | | Recurrent ACS + LDL-C ≥100 | <15 | <$50,000 | High value |

Payer Coverage: Where Things Stand

Despite improved economics, U.S. payer coverage for alirocumab per its FDA-approved labeling remains heavily restricted. Most commercial and Medicare Part D plans require:

• Documented trial of maximally tolerated statin therapy (typically high-intensity for ≥8 weeks)
• LDL-C still above a threshold (often ≥70 mg/dL, sometimes ≥100 mg/dL)
• Established ASCVD or familial hypercholesterolemia diagnosis
• Prior authorization with specialist attestation
• Some plans still require documentation of ezetimibe trial before approving a PCSK9 inhibitor

The 2018 ACC/AHA cholesterol guidelines gave PCSK9 inhibitors a Class IIa recommendation for patients with clinical ASCVD at very high risk whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe. The 2022 ACC Expert Consensus Decision Pathway updated this, reinforcing that PCSK9 inhibitors should be considered when LDL-C remains above goal despite statin and ezetimibe, and explicitly acknowledging improved cost-effectiveness after price reductions.

European access follows a different pattern. The UK's National Institute for Health and Care Excellence (NICE) approved alirocumab for secondary prevention only in patients with LDL-C persistently above specific thresholds despite optimized lipid therapy, contingent on a confidential discount that brought the effective price well below list.

Limitations of Existing Economic Models

Every published cost-effectiveness analysis of ODYSSEY OUTCOMES carries structural limitations worth noting:

Short trial duration, long extrapolation. The trial ran for a median of 2.8 years. Models project costs and benefits over 30+ year horizons. The assumption that relative risk reduction persists indefinitely after treatment stops has no direct evidence. If benefit attenuates, models overestimate QALYs gained.

Utility estimates borrowed, not measured. None of the published models used utility data collected within ODYSSEY OUTCOMES itself. Values came from prior ACS literature, introducing potential bias if the alirocumab-treated population experienced different quality-of-life profiles.

Injection burden not fully captured. Subcutaneous injections every two weeks carry disutility that most models either ignored or assigned minimal decrements to. For some patients this burden is significant enough to affect adherence and real-world effectiveness.

Adherence assumptions. Models assumed trial-level adherence (~97% in ODYSSEY OUTCOMES). Real-world PCSK9 inhibitor adherence data from claims analyses show 12-month persistence rates closer to 55-65%, which would reduce both costs (fewer doses purchased) and effectiveness (fewer events prevented), with uncertain net effect on the ICER.

Comparator evolution. Bempedoic acid (FDA-approved 2020) and inclisiran (FDA-approved 2021) were not available comparators when ODYSSEY OUTCOMES models were built. Updated analyses incorporating these alternatives as sequential steps before PCSK9 inhibitor initiation could shift the position of alirocumab in the treatment pathway and alter its relative cost-effectiveness.

The Individual Patient Calculation

For a clinician and patient deciding whether to start alirocumab after ACS, the economic framing reduces to a practical question: given this patient's residual risk profile, what is the expected benefit, and does it justify the out-of-pocket cost and injection burden?

At current net pricing (estimated $4,000-$6,000 per year after rebates and negotiation), for a patient with recent ACS, LDL-C ≥100 mg/dL on maximally tolerated statin, and at least one additional risk amplifier (diabetes, PAD, recurrent events, or polyvascular disease per ODYSSEY OUTCOMES subgroup data), the modeled cost per QALY falls below $50,000. That represents a strong value proposition by conventional U.S. thresholds.

For a patient with post-ACS LDL-C of 75 mg/dL, no diabetes, single-vessel disease, and no recurrent events, the absolute benefit is smaller and the cost-per-QALY rises above $100,000, pushing the value calculation into uncertain territory where patient preference, copay burden, and injection tolerance become decisive.

The Praluent prescribing information does not stratify by cost-effectiveness, but clinicians who integrate residual risk assessment with economic awareness can identify the patients most likely to derive high value from treatment.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed
• Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY OUTCOMES trial. JAMA Cardiol. 2019;4(6):560-568. PubMed
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
• Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering. J Am Coll Cardiol. 2022;80(14):1366-1418. PubMed
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387-396. PubMed
• Praluent (alirocumab) prescribing information. Regeneron/Sanofi. FDA Label